Matthew Kapusta Sells 21,082 Shares of uniQure (NASDAQ:QURE) Stock

uniQure N.V. (NASDAQ:QURE) CEO Matthew Kapusta sold 21,082 shares of the firm’s stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $45.16, for a total value of $952,063.12. Following the completion of the transaction, the chief executive officer owned 519,227 shares of the company’s stock, valued at approximately $23,448,291.32. The trade was a 3.90% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

uniQure Stock Performance

Shares of NASDAQ QURE opened at $43.49 on Thursday. uniQure N.V. has a 12 month low of $8.73 and a 12 month high of $71.50. The company has a current ratio of 10.40, a quick ratio of 10.40 and a debt-to-equity ratio of 0.33. The stock has a market cap of $2.74 billion, a price-to-earnings ratio of -12.50 and a beta of 0.90. The company has a 50 day simple moving average of $31.99 and a two-hundred day simple moving average of $24.29.

uniQure (NASDAQ:QURE) last announced its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share for the quarter, topping the consensus estimate of ($0.88) by $0.03. uniQure had a negative return on equity of 145.81% and a negative net margin of 1,154.42%.The company had revenue of $3.56 million for the quarter, compared to the consensus estimate of $5.21 million. As a group, analysts predict that uniQure N.V. will post -3.56 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on QURE shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of uniQure in a research note on Friday, June 26th. Wall Street Zen raised shares of uniQure from a “sell” rating to a “hold” rating in a report on Saturday, March 28th. HC Wainwright raised their price target on shares of uniQure from $50.00 to $80.00 and gave the company a “buy” rating in a research report on Monday, June 29th. Stifel Nicolaus set a $28.00 price objective on shares of uniQure in a report on Tuesday, May 5th. Finally, Chardan Capital upped their price objective on shares of uniQure from $31.00 to $37.00 and gave the stock a “buy” rating in a research report on Thursday, April 30th. Twelve research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $64.17.

Hedge Funds Weigh In On uniQure

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. State Street Corp raised its position in shares of uniQure by 123.8% during the 4th quarter. State Street Corp now owns 3,231,043 shares of the biotechnology company’s stock worth $77,319,000 after purchasing an additional 1,787,033 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in uniQure by 155.3% in the 4th quarter. JPMorgan Chase & Co. now owns 2,934,626 shares of the biotechnology company’s stock worth $70,226,000 after buying an additional 1,785,275 shares during the last quarter. Avoro Capital Advisors LLC increased its stake in uniQure by 38.4% during the 4th quarter. Avoro Capital Advisors LLC now owns 6,150,000 shares of the biotechnology company’s stock worth $147,170,000 after buying an additional 1,705,556 shares in the last quarter. Orbimed Advisors LLC increased its stake in uniQure by 189.7% during the 1st quarter. Orbimed Advisors LLC now owns 2,136,149 shares of the biotechnology company’s stock worth $34,926,000 after buying an additional 1,398,749 shares in the last quarter. Finally, MPM Bioimpact LLC acquired a new position in shares of uniQure during the fourth quarter valued at approximately $33,062,000. 78.83% of the stock is owned by hedge funds and other institutional investors.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.